pharmaphorum July 18, 2024
The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector’s role in rising healthcare costs in the US.
The hearing – scheduled for 23rd July – is part of an ongoing investigation by the committee into PBMs’ alleged anticompetitive practices launched last year and spearheaded by chairman James Comer (R-Ky).
It comes right on the heels of a Federal Trade Commission (FTC) report that concluded that the market dominance of the top companies has “dire consequences,” increasing prescription drug costs, hurting independent pharmacies, and compromising patient care. The regulator has also accused the PBMs of failing to cooperate wholly with its investigation, which has been...
Today's Sponsors
Today's Sponsor